Taken together, these data are consistent with a neuroprotective effect of inhibition of the potent anaphylatoxin C5a–C5aR1 interaction, while leaving C1q and C3 immunoprotection intact, making C5a–C5aR1 signaling a promising therapeutic target for AD. The gene discussed is C3; the disease is Alzheimer disease.